Troxerutin

Preparation

Troxerutin can be prepared using starch as a filler and 95% ethanol as a wetting agent to form a suitable soft mass. After granulation and drying, the granules are sized using a nylon sieve. The mixture is then uniformly mixed with magnesium stearate and talc as lubricants before compression into tablets. The resulting tablets have a smooth and delicate appearance, good tablet hardness, stable tablet weight variation, and qualified content. This process improves the flowability and outflow rate of troxrutin powder, resulting in a fast and uniform granule flow rate, thus ensuring stable tablet weight variation. Granulation also reduces the amount of fine powder, minimizing contact between the powder and the punch, and preventing die pulling. This process requires no drying, consumes little energy, and is low-cost, making it suitable for industrial production.

Chemical Properties

Yellow Powder

Originator

Venoruton,Novartis Co

Uses

vasoprotectant

Uses

Used in the treatment of venous disorders

Uses

Troxerutin, a derivative of the naturally occurring bioflavonoid rutin, is thought to inhibit red cell and platelet aggregation, improve erythrocyte deformability, and improve plasma viscosity retinal microcirculation. A double-blind randomized clinical trial compared troxerutin with placebo in 27 patients with CRVO. The limitations of the study included a small number of patients and short follow-up time.

Manufacturing Process

In a nitrogen atmosphere 120 g of caustic soda (3 moles) in solution are added to 610 g of rutin (1 mol) suspended in 2 litres of water, the mixture being vigorously agitated by a mechanical stirrer, 241.5 g of ethylene chlorohydrin being then introduced at 55°C for 10 min. When all the chlorohydrin has been thus added the temperature is progressively raised to 75°C and maintained at this level for 2 hours. After cooling, in a nitrogen atmosphere, the pH value adjusted to 5 by the addition of dilute hydrochloric acid. The solution is kept in an ice box for 24 hours and then filtered to remove any impurities. At reduced pressure the solution is evaporated until dry, the residue taken up in 3 litres of boning methanol which dissolves the tri-(β-hydroxyethyl)rutin formed and leaves the sparingly soluble sodium chloride behind. The tri-(β-hydroxyethyl)rutin is recovered from its methanolic solution either by evaporation and refrigeration, or by evaporation precipitation with absolute ethanol. In either case tri-(β-hydroxyethyl)rutin obtained is in the form of small very hygroscopic crystals which contain alcohol of crystallization.These crystals are quickly shaken washed in a little cold absolute ethanol and then dried in vacuum at 100°C. 680 g of anhydrous tri-(β-hydroxyethyl)rutin are thus obtained in the form of a yellow powder which melts at 156°C.GB Patent No. 833,174; April 21, 1960; Assigned to Zyma S.A., a Swiss Corporation, of Route Etraz, Nyon Canton of Vaud, Switzerland

Therapeutic Function

Topical venotonic

Biological Activity

Troxerutin is a brain penetrant, vasoprotective flavonol isolated from Sophora japonica, which is present in many other plants including grains, fruits, and vegetables. Troxerutin exhibits multiple biological activities including anti-oxidative, anti-radiation, and anti-inflammatory. Recent study indicates th at troxerutin improves the synaptic failure induced by Aβ peptide. It appears th at Troxerutin could promote radioprotection by stimulating NEAT1 to upregulate PDPK1 expression by suppressing miR-147.

target

VEGFR | Wnt/β-catenin | NF-kB | SOD | PI3K | Akt

References

[1] Patent: CN104478972, 2017, B. Location in patent: Paragraph 0018; 0019; 0020; 0021; 0022; 0023; 0024-0031
[2] Patent: CN106892950, 2017, A. Location in patent: Paragraph 0018-0026
[3] Chinese Chemical Letters, 2013, vol. 24, # 3, p. 223 - 226
[4] Patent: CN103601772, 2016, B. Location in patent: Paragraph 0011-0014
[5] Patent: CN104447914, 2017, B. Location in patent: Paragraph 0013; 0014